Related Experiment Video
Updated: Dec 22, 2025

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
Published on: August 15, 2016
Sulfobutylether-β-cyclodextrin
Valentino J Stella1, Roger A Rajewski1
1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, USA.
Abstract:
This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution.
Related Concept Videos
Intramolecular Claisen Condensation of Dicarboxylic Esters: Dieckmann Cyclization
β-Dicarbonyl Compounds via Crossed Claisen Condensations
Esters to β-Ketoesters: Claisen Condensation Overview
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Preparation and Reactions of Sulfides
Esters to β-Ketoesters: Claisen Condensation Mechanism

